Telix Pharmaceuticals (TLX) H.C. Wainwright 28th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 28th Annual Global Investment Conference summary
17 Sep, 2026Business overview and infrastructure
Vertically integrated theranostic radiopharma model combines diagnostics and therapeutics for each target.
Imaging business commercialized with $1 billion in annual sales, mainly from prostate cancer imaging; recent brain cancer approval adds to portfolio.
Cash flow from imaging products funds a robust R&D pipeline, including three phase III trials.
Major focus areas are urology and neuro-oncology, with global manufacturing and distribution infrastructure established since 2020.
Delivered 3 million patient doses last year, demonstrating commercial scale.
Financial guidance and outlook
Guidance for 2026 revised toward the upper end following a strong first half; current trajectory remains positive.
No plans for casual guidance adjustments; maintaining current guidance for the year.
Precision medicine and imaging pipeline
Pixclara, the first PET imaging agent for glioma, recently FDA approved; addresses a high unmet need in neuro-oncology.
Market opportunity estimated at 20,000–25,000 scans, with potential for multiple scans per patient and significant upside.
Expansion into metastatic brain tumor imaging could multiply the addressable market by four to five times.
Synergies expected from existing relationships in nuclear medicine and neurology.
Latest events from Telix Pharmaceuticals
- BiPASS data and Pixclara reimbursement milestones set up key 2027 growth catalysts.TLX
Bell Potter Healthcare Conference - A broad radiopharma pipeline and supply expansion set up a major 2027 catalyst year.TLX
UBS Global Biopharma Conference 2026 - FY26 guidance and ITM integration underpin a 2027 growth step-up.TLX
CMD 2026 - Revenue rose 214%, turning FY2023 profitable as cash flow funded pipeline growth.TLX
H2 2023 - Revenue rose 19% YoY as Pixclara approval and the ITM merger advanced growth plans.TLX
Q3 2026 TU - Late-stage pipeline, global expansion, and strategic deals drive radiopharma leadership.TLX
R&D Day 2026 - US$1.65B merger creates a global radiopharma leader with EBITDA positivity targeted by 2027.TLX
M&A announcement - FDA approval, pipeline expansion, and integrated distribution drive radiopharma leadership.TLX
Morgan Stanley 24th Annual Global Healthcare Conference - Revenue up 22% to $477.3M, net profit $38.3M, margin and pipeline gains drive strong outlook.TLX
H1 2026